Smith & Nephew announced compelling new randomized control trial data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the Regeneten bioinductive Implant in isolation. The study, published in the Orthopaedic Journal of Sports Medicine, showed early recovery time was halved for patients returning to daily activities compared to a traditional suture anchor repair. Specifically, patients returned to driving in 2.3 weeks versus 5.1 weeks and reported a better quality of life at six weeks and three months. “We conducted a randomised controlled study of patients with symptomatic partial-thickness rotator cuff tears and found that those patients treated with the tendon sparing REGENETEN Bioinductive Implant recovered functional independence much faster than patients treated with standard surgery. Time to sling removal, return to driving, office duties, and household tasks all occurred sooner with the REGENETEN Bioinductive Implant. Importantly, these milestones were achieved without an increase in patients’ pain and without compromise in rotator cuff tendon healing on 12-month MRI scans. This study marks an important shift in the evolving standard of care for partial-thickness rotator cuff tears,” said Allan Wang, clinical professor of orthopedic surgery at the University of Western Australia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith & Nephew Grants New Executive Share Awards and Tightens Governance Under Long-Term Incentive Plans
- Smith & Nephew Updates Share Capital and Voting Rights as of 31 March 2026
- Smith & Nephew Discloses Executive Share Vesting and Sales for Tax on 23 March 2026
- Cevian Doubles Stake in Smith & Nephew to Just Over 10%
- Smith & Nephew Publishes 2025 Annual Report and Calls 2026 AGM
